3月4日,康宁杰瑞制药发布公告称,公司首次实现年度盈利,预期集团在截至2024年12月31日止年度取得利润不少于人民币1.5亿元。再鼎医药近期也发布了2024年度业绩,其总收入为3.990亿美元,同比增长50%;2025年全年收入预期为5.6亿~5.9亿美元。康宁杰瑞制药绩后大涨超10%,领涨恒生医药ETF持仓股,再鼎医药、巨子生物、诺诚健华等涨幅靠前。恒生医药 ETF(159892)跟踪恒生生物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.